Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zynerba Pharmaceuticals
Devon, Pennsylvania, United Stateszynerba.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Zynerba’s lead asset Zygel™ has shown positive data in Phase 2 trials for both Fragile X syndrome and 22q11.2 deletion syndrome and was being evaluated in a pivotal Phase 3 trial (“RECONNECT”) for FXS at the time of acquisition by Harmony Biosciences.[1][7] The product has received orphan drug designation from the FDA and European Commission for both conditions.[4]
> “Zygel™…is currently being evaluated in a pivotal Phase 3 clinical trial for patients living with FXS…” [7]
> “Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome…” [1]
No products are yet approved or commercialized.- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Synthetic cannabinoids (specifically cannabidiol)Transdermal gel delivery
- Industry
- Biotech
Beyond the preview
Go deeper on Zynerba Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zynerba Pharmaceuticals.